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Bisphenol A (BPA) is suspected to be associated with several chronic metabolic diseases. The aim of the present
study was to review the epidemiological literature on the relation between BPA exposure and the risk of cardiometabolic
disorders. PubMed and Embase databases were searched up to August 2014 by two independent investigators using
standardized subject terms. We included observational studies (cohort, case–control and cross-sectional studies) carried
out in children or adults, measuring urinary BPA (uBPA), including at least 100 participants and published in English. The
health outcomes of interest were diabetes, hyperglycemia, measures of anthropometry, cardiovascular disease (CVD) and
hypertension. Data were extracted and meta-analyzed when feasible, using a random-effects model. Thirty-three studies
with sample size ranging from 239 to 4811 met the inclusion criteria, including five with a prospective design. Twelve
studies reported on diabetes or hyperglycemia, 16 on anthropometry, 6 on CVD and 3 on hypertension. Evidence for a
positive association between uBPA concentrations and diabetes, overweight, obesity, elevated waist circumference (WC),
CVD and hypertension was found in 7/8, 2/7, 6/7, 5/5, 4/5 and 2/3 of the cross-sectional studies, respectively. We
were able to conduct outcome-specific meta-analyses including 12 studies. When comparing the highest vs. the
lowest uBPA concentrations, the pooled ORs were 1.47 (95 % CI: 1.21–1.80) for diabetes, 1.21 (95 % CI: 0.98–1.50)
for overweight, 1.67 (95 % CI: 1.41–1.98) for obesity, 1.48 (95 % CI: 1.25–1.76) for elevated WC, and 1.41 (95 % CI:
1.12–1.79) for hypertension. Moreover, among the five prospective studies, 3 reported significant findings, relating
BPA exposure to incident diabetes, incident coronary artery disease, and weight gain. To conclude, there is evidence from
the large body of cross-sectional studies that individuals with higher uBPA concentrations are more likely to suffer from
diabetes, general/abdominal obesity and hypertension than those with lower uBPA concentrations. Given the potential
importance for public health, prospective cohort studies with proper adjustment for dietary characteristics and
identification of critical windows of exposure are urgently needed to further improve knowledge about potential causal
links between BPA exposure and the development of chronic disease.
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In recent decades, large and rapid increases in diabetes
and obesity prevalence have been observed worldwide.
Apart from traditional risk factors such as family history,
sedentary lifestyle and energy dense dietary intake, atten-
tion has recently turned to environmental toxicants
called endocrine-disrupting chemicals (EDCs) because of
their ability to interfere with synthesis, secretion, trans-
port, metabolism, binding action, or elimination of nat-
ural blood-borne hormones, and to induce obesogenic
or diabetogenic effects [1]. In particular, bisphenol A (BPA)
has been strongly suspected as a potential contributor to
these disease aetiologies [2–5].
BPA is a synthetic monomer used in the manufacture of
polycarbonate plastics and epoxy resins, with a world
production estimated at 3.8 million tons in 2006 [6]. Im-
portantly, this production of BPA is expected to increase
further in the coming years, given the robust demand for
polycarbonate plastics and epoxy resins from China [7]
and other emerging markets. The primary source of hu-
man exposure to BPA is presumed to be via the ingestion
of food which has been stored or reheated in BPA-lined
containers, but recent data suggest there is at least some
exposure from drinking water, dental sealants, thermal
paper and, to a lesser extent, inhalation of household dust
particles [8–12]. BPA is ubiquitous in our environment, as
evidenced by the fact that over 90 % of individuals have
detectable levels of BPA present in their urine [13], which
is the primary route of excretion in humans [14]. BPA has
been found in neonates, children and adults [13], and can
be measured in a range of bodily fluids and tissues, includ-
ing urine, blood, saliva, placental tissue, adipose tissue and
breast milk [13, 15].
There is accumulating in vitro and animal data (small
and large animal) supporting a role of BPA in the develop-
ment of diabetes, supporting a role of BPA in the develop-
ment of diabetes, cardiovascular disease (CVD) and obesity.
BPA is structurally similar to 17β-estradiol and thus binds
to estrogen-related receptors (ER) such as ERα, ERβ and
ERγ, the G protein-coupled estrogen receptor GPR30, and
the peroxisome proliferator-activated receptor gamma
(PPAR-γ) [16, 17]. While the mechanisms of action are not
fully understood, binding of BPA to these receptors has
been shown to induce insulin resistance, adipogenesis,
pancreatic beta-cell dysfunction, inflammation, and oxida-
tive stress [3, 18–20]. At concentrations typically seen in
humans, BPA has been shown to act via extranuclear ERα
[21] and ERβ [22]. These two studies used β-cells and
whole islets of Langerhans from mice lacking ERα and
ERβ and humans to demonstrate that the low dose effect of
BPA is mediated via these estrogen receptors. Other experi-
mental studies have also shown that BPA at environmen-
tally relevant doses could inhibit the release of adiponectin,
an adipokine that protects humans from obesity-relatedmetabolic syndrome [23]. It also may have direct pro-
angiogenic effects on human primary endothelial cells,
suggesting that the human endothelium may be an im-
portant target for BPA [24]. Recently, Marmugi et al.
showed that BPA exposure for 8 months in adult mice
resulted in increased adipose tissue mass, hypergly-
caemia, glucose intolerance, hypercholesterolemia and
increased cholesterol biosynthesis by the liver [25].
However, the relevance of animal studies to humans
remains unclear due to enterohepatic recirculation in
rodents, resulting in a slower rate of BPA excretion
compared with humans [14].
Given the ongoing policy debate on the possible public
health benefits of minimizing BPA exposure, there is
an urgent need for research to adequately evaluate
cardiometabolic health in relation to BPA exposure.
The past 10 years have seen a rapid increase in pub-
lished reports of human, population-based epidemio-
logical studies linking BPA to obesity, diabetes and
CVD, most of which are cross-sectional studies. To
date, three reviews have evaluated the available litera-
ture concerning BPA and chronic disease in humans
[26–28]. However, the authors did not perform meta-
analysis and, as the body of literature is growing rapidly,
important new evidence can appear within short timelines
[29]. Thus the aims of the present review were:
1. to provide insight into the most recent
epidemiological evidence on the association between
urinary BPA (uBPA) concentrations and chronic,
cardiometabolic disorders (diabetes, overweight,
obesity, CVD and hypertension);
2. to carry out meta-analysis when feasible; and
3. to identify the gaps in research that will allow for a
comprehensive assessment of possible risk to
humans.
Methods
This review follows PRISMA guidelines for systematic
reviews of observational studies [30].
Eligibility criteria
Studies were included if the following inclusion criteria
were met:
– Participants – Human studies including adults or
children (however only diabetes in adults, in an
attempt to limit the analysis to type 2)
– Outcomes – Studies examining diabetes,
hyperglycemia, measures of anthropometry/
adiposity, CVD or hypertension. Surrogate
cardiometabolic outcomes such as blood cholesterol
levels and insulin sensitivity indices (e.g.,
Homeostasis Model Assessment of Insulin
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Check Index [QUICKI], Matsuda Index) were not
considered.
– Exposure – Urinary measures of BPA and/or BPA
metabolites (studies examining BPA exposure in
pregnant women in relation to outcome in the
offspring were beyond the scope of this review)
– Sample size – Studies including at least 100
participants,
– Language – Studies published in English,
– Appropriate statistical adjustment – Models
including adjustment for confounders (at least age
and gender).
Information sources and search
PubMed and Embase databases were searched to identify
potential studies for this review published up to August
2014. The keywords (and corresponding Medical Subject
Heading [MeSH] terms for the search in PubMed) ‘body
mass index’, ‘overweight’, ‘obesity’, ‘waist circumference’,
‘body weight’, ‘abdominal obesity’, ‘cardiovascular disease’,
‘coronary heart disease’, ‘diabetes’, ‘hypertension’, ‘blood
pressure’, ‘insulin resistance’, ‘glucose intolerance’ were
combined with the Boolean operator ‘OR’. The key term
‘Bisphenol A’ was entered and combined with the former
using the Boolean operator ‘AND’. The full electronic
search strategy in PubMed is reported in the Additional file
1: Figure S1. References from identified studies were hand-
searched to ensure that no relevant studies were missed.
Study selection and data extraction
All the identified publications were evaluated for relevance
by two independent reviewers (DJM, FR), on the basis of
their titles and abstracts; any disagreement was resolved
by discussion. Full texts of the selected abstracts were then
checked for the inclusion criteria by the reviewers. Final
eligibility of studies was decided by consensus.
Summary data for included studies were extracted into
a standardized tool that included: study design, country,
population, sample size, age, gender, ethnicity, outcome
definition, method of exposure measurement, uBPA
levels and categorization, results expressed as adjusted
odds ratios (OR), hazard ratios (HR) or β-coefficients,
and variables used in adjustment.
The quality of individual studies, with regard to the
outcomes of interest, was independently assessed by two
investigators. We utilised a scoring system based on the
established OHAT guidelines [31] adapted to reflect the
characteristics of the included studies: longitudinal design
(2 points), population-based study (1 point), outcome as-
sessment including measurements (1 point), collection of at
least 2 urine samples per participant (1 point), control
for urine dilution (1 point), adjustment for dietary
intake (1 point), and adjustment for socioeconomicvariables (1 point). Studies were then classified as ‘low
quality’ (total score between 0 and 2), ‘medium quality’
(total score between 3 and 5), or ‘high quality’ (total
score between 6 and 8).Meta-analysis
We appraised each study to examine sources of heterogen-
eity, including difference in clinical outcomes and exposure
measurements. Participant overlap between related studies
was examined. For studies that used similar sources of data
(e.g., surveys of National Health and Nutrition Examination
Survey [NHANES], over concurrent periods and similar
age range), only the study with the largest data set was in-
cluded in the meta-analysis.
For each outcome, two studies with comparable out-
come and exposure definitions were sufficient to per-
form a meta-analysis. For anthropometric outcomes, we
performed pooled and separate analysis for children and
adults. ORs with corresponding confidence intervals
(CIs) were extracted from the most adjusted model. For
summary purposes, we pooled OR estimates comparing
extreme categories of uBPA levels (the highest vs. lowest
uBPA levels). A random effects model was used. The
logarithm of the OR and its standard error (SE) was cal-
culated using the formula of log (upper limit of 95 % CI)
minus log (lower limit of 95 % CI) divided by 3.92
(2*1.96, the 97.5th percentile of the standard normal dis-
tribution) and was entered into REVMAN 5.1 software
(REVMAN 2011). Heterogeneity between studies was
tested using Chi-squared test and quantified by calculat-
ing the I2 statistic. We produced forest plots to visually
assess the individual study ORs and overall ORs, with
corresponding 95 % CIs.Results
Study selection
The initial search identified 953 studies in total. Of
these, 895 studies were excluded after screening of the
titles/abstracts (studies did not meet inclusion criteria
e.g., were animal or in vitro studies, reported only serum
BPA levels, or were review/commentary articles). Fifty
eight studies were thus identified and reviewed in full-
text versions, from which 33 studies were selected to be
included in the systematic review (Fig. 1).
Twelve independent cross-sectional studies were se-
lected for quantitative synthesis, making meta-analysis
possible for 5 health outcomes: diabetes, overweight,
obesity, elevated waist circumference (WC) and hyper-
tension. Individual and pooled OR estimates are shown
in the Additional file 1: Figure S2. Studies included and
excluded from meta-analysis and reasons for exclusion
are summarized in the Additional file 1: Table S1.
Initial search in 
PubMed yielded 528
articles
Abstracts reviewed by 2
authors (DJM & FR)
58 full-text articles 
assessed for eligibility
25 full-text articles excluded:
- 9 meeting abstracts without
full text
- 9 without outcome of interest
- 6 review/commentary articles
- 1 with unadjusted results
33 articles eligible for 
qualitative synthesis
Initial search in 
Embase yielded 834
articles
953 articles identified 
after duplicates removed
895 articles excluded after 
screening of the title/abstract
12 Diabetes/hyperglycemia
16 Indicators of anthropometry
6 Cardiovascular disease
3 Hypertension
12 articles eligible for 
quantitative synthesis
3 Diabetes
5 Overweight
3 Obesity
4 Elevated waist circumference
2 Hypertension
Fig. 1 Flow diagram of the search strategy for the systematic review (some studies reported on several outcomes)
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Characteristics for each of the 33 articles included in the
review are summarized in Table 1 and detailed in the
Additional file 1: Table S2.
Study design and population
This systematic review includes 28 cross-sectional and 5
longitudinal studies, drawn from 19 different study pop-
ulations and 6 different countries. Sample sizes ranged
from 239 [32] to 4811 [33] representing a total of 69,486
participants, not accounting for participant overlap
across publications utilizing data from the same study
populations.
Among the cross-sectional studies, 16 (57 %) used
study populations from the NHANES study (cycles
ranging from the years 2003 to 2010) [33–48]. Poten-
tial overlap between all publications using data from
NHANES is summarized in the Additional file 1: Table S3.
Five cross-sectional studies (18 %) used Chinese popula-
tions [49–53], including two studies using the samepopulation sample from Songnan Community in Shanghai
[51, 52]. Four cross-sectional studies (14 %) used a Korean
population [54–57], while other single studies were con-
ducted in Italians [58], Iranians [32], and British popu-
lations [59]. Of the 5 prospective studies, one was on
the EPIC-Norfolk study (UK) [60] and 4 from U.S.
cohorts, NHS and NHSII [61, 62], HOME [63] and
CHAMACOS [64].
Of the 16 NHANES publications, 11 investigated adults
[34, 36, 37, 39–46], while four restricted their study
population to children/teenagers [35, 38, 47, 48]. One
further study examined adults for CVD outcomes; how-
ever this study was excluded from the diabetes out-
come analysis because the study population included a
mixed sample of children and adults [33]. Of the 12
other cross-sectional studies, 10 were conducted in
adult populations [32, 51–59], and 2 in school-age chil-
dren [49, 50]. Three of the prospective studies were
conducted in adults [60–62]. Of the two in children
[63, 64], follow-up for the infants in the HOME study
Table 1 Summary characteristics of studies included in the
systematic review (n = 33 studies)
Study characteristics n
Year of publication
2008 1
2009 0
2010 2
2011 5
2012 10
2013 8
2014 7
Geographical
setting
Asia 10
Europe 3
North America 20
Design
Cross-sectional 28
Prospective 5
Age category
Children 8
Adults 25
Gender
Mixed 30
Women only 3
Sample size
<500 5
500–1000 4
1001–2000 9
2001–3000 6
3001–4000 6
4001–5000 3
Health outcomesa
Diabetes 9
Prediabetes 1
Hyperglycemia 2
Overweight 7
Obesity 7
Elevated waist
circumference
5
Cardiovascular
disease
6
Hypertension 3
Urinary sample
Spot sample 27
First-morning-void
sample
3
Table 1 Summary characteristics of studies included in the
systematic review (n = 33 studies) (Continued)
Second-morning
void sample
1
12-h sample 1
24-h sample 1
aSome studies reported on several outcomes
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CHAMACOS cohort at 5 and 9 years old [64].
All NHANES cycles as well as the NHS, NHSII and
HOME cohorts comprised multiple ethnicities, but were
predominantly non-Hispanic white. Mothers of children
from the CHAMACOS cohort were mostly Latina. In 10
publications, all participants were Asian, from China
[49–53], South Korea [54–57] or Iran [32].
Outcomes
This review included 12 publications on abnormal glu-
cose tolerance (9, 2 and 1 with outcomes of diabetes,
hyperglycemia and prediabetes, respectively), 16 publica-
tions on anthropometry (7 with an outcome of over-
weight, 7 with obesity and 5 with elevated WC), 6
publications on CVD and 3 on hypertension.
Urinary BPA assessment and levels
All the studies used total (unconjugated and conjugated)
uBPA concentration as the exposure variable. The ma-
jority of studies relied on a single uBPA measurement,
however 3 assessed BPA exposure using repeated mea-
surements: 2 follow-up assessments in paediatric studies
[63, 64], and up to 5 measurements during the study
period in an adult study [54].
The highest uBPA mean concentration was reported
in a study in children within the NHANES 2003/08 cy-
cles [35], with a mean (SE) of 5.0 (0.3) ng/mL in boys
and 4.6 (0.3) ng/mL in girls. The earliest NHANES
(2003/2004) study had the highest mean levels of BPA,
and median BPA concentration followed a downward
trend across subsequent NHANES cycles [37]. The low-
est uBPA concentration was reported in a cross-
sectional study conducted in Chinese school children in
2011 [50], with a median (interquartile range, IQR) of
0.60 (0.20–1.37) ng/mL.
Covariates
Tables 2, 3 and 4 describe all variables used for the adjust-
ment in the statistical analyses for each separate publica-
tion. All models were adjusted for at least age and gender.
In order to correct for urine dilution, the majority of stud-
ies adjusted for an indicator of renal function, either urin-
ary creatinine [33–40, 42, 45–48, 52, 55–57, 60–62, 64],
estimated glomerular filtration rate (eGFR) [51], specific
gravity [50], or serum creatinine [32]. Four studies
Table 2 Summary of results in studies used as primary data: diabetes, prediabetes and hyperglycemia (n = 12 publications)
Reference Outcomes & definitions used Urinary BPA categorisation Main results Adjustment in model(s) used for review
Prevalent diabetes (8 publications)
Ahmadkhaniha et al. 2014
[32]
Type 2 diabetes: self-reported
and doctor-diagnosed T2D
according to the ADA guideline
(FPG >126 mg/dL, HbA1c >6.5 %)
for more than one year
BPA in two groups based on the median
(<0.85 and ≥0.85 μg/L)
OR = 57.6
(21.1–157.05)
Age, sex, BMI, hypertension, serum triglyceride
level, serum cholesterol level, serum creatinine
(smoking and consumption of sugared drinks
in plastic bottles or canned food in two past
weeks were exclusion criteria)
Casey & Neidell 2013 [37] Diabetes: self-report of doctor
diagnosis
BPA continuous (not log-transformed) Per SD increase: Age, sex, urinary creatinine concentration, race/
ethnicity, income, smoking, body mass index,
waist circumference, veteran/military status,
citizenship status, marital status, household
size, pregnancy status, language at subject
interview, health insurance coverage, employment
status in the prior week, consumption of bottled
water in the past 24 h, consumption of alcohol,
annual consumption of tuna fish, presence of
emotional support in one’s life, being on a diet,
using a water treatment device, access to a
routine source of health care, vaccinated for
Hepatitis A or B, consumption of dietary
supplements (vitamins or minerals), inability
to purchase balanced meals on a consistent basis +
survey cycle for pooled analyses
2003/04: OR = 1.398 (1.183–1.653)
2005/06: OR = 1.008 (0.861–1.181)
2007/08: OR = 0.716 (0.500–1.025)
Pooled 2003/08: OR = 1.065 (0.973–
1.166)
BPA continuous (log-transformed) Per 10-fold increase:
2003/04: OR = 1.492 (1.267–1.757)
2005/06: OR = 1.230 (0.894–1.694)
2007/08: OR = 0.932 (0.759–1.146)
Pooled 2003/08: OR = 1.202 (1.049–
1.377)
BPA in quartiles (ng/mL): Q1: <1.2; Q2:
1.2–2.2; Q3: 2.3–4.2; Q4: >4.2
Pooled 2003/08:
Q2 vs. Q1: OR = 1.443 (0.982–2.119)
Q3 vs. Q1: OR = 1.512 (0.998–2.289)
Q4 vs. Q1: OR = 1.760 (1.137–2.724)
Kim & Park 2013 [56] Type 2 diabetes: self-reported and
doctor-diagnosed
BPA in quartiles (ng/mL): Q1: <1.36; Q2:
1.36–2.14; Q3: 2.15–3.32; Q4: >3.32
Q2 vs. Q1: OR = 1.23 (0.62–2.43) Urinary creatinine, age, sex, BMI, education, cigarette
smoking, income, place of residence
Q3 vs. Q1: OR = 1.17 (0.60–2.28)
Q4 vs. Q1: OR = 1.71 (0.89–3.26)
p for trend = 0.374
Lang et al. 2008 [39] Diabetes: self-report of doctor
diagnosis
BPA continuous Per SD increase: Age, sex, race/ethnicity, education, income,
BMI, WC, smoking status, urinary creatinine
OR = 1.39 (1.21–1.60)
Melzer et al. 2010 [40] Diabetes: self-report of doctor
diagnosis
BPA continuous Per SD increase: Age, gender, ethnicity, education, income,
BMI, WC, smoking status, urinary creatinine
2003/04: OR = 1.40 (1.25–1.56)
2005/06: OR = 1.02 (0.76–1.38)
Pooled 2003/06: OR = 1.24 (1.10–
1.40)
Ning et al. 2011 [51] Type 2 diabetes: FPG ≥7.0 mmol/L
or plasma glucose ≥11.1 mmol/L
two hours after oral glucose
BPA in quartiles (ng/mL): Q1: ≤0.47;
Q2: 0.48 –0.81; Q3: 0.82–1.43; Q4: >1.43
Q2 vs. Q1: OR = 1.30 (1.03–1.64) Age, sex, educational level, family history of
diabetes, WC, systolic blood pressure, ln(TG
level), ln(hsCRP level), ln(ALT level), estimatedQ3 vs. Q1: OR = 1.09 (0.86–1.39)
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Table 2 Summary of results in studies used as primary data: diabetes, prediabetes and hyperglycemia (n = 12 publications) (Continued)
tolerance test or use of diabetes
medication
glomerular filtration rate, albumin level, total
bilirubin level
Q4 vs. Q1: OR = 1.37 (1.08–1.74)
p for trend not statistically significant
Shankar & Teppala
2011 [42]
Diabetes: fasting serum glucose
>126 mg/dL or non-fasting serum
glucose >200 mg/dL or HbA1c
>6.5 % or self-reported current use
of oral hypoglycemic medication
or insulin
BPA in quartiles (ng/mL): Q1: <1.10;
Q2: 1.10–2.10; Q3: 2.11–4.20; Q4: >4.20
Q2 vs. Q1: OR = 1.42 (1.03–1.96) Age, gender, race-ethnicity, education
categories, smoking, alcohol intake, BMI,
systolic and diastolic blood pressure, urinary
creatinine, total cholesterol
Q3 vs. Q1: OR = 1.48 (1.05–2.08)
Q4 vs. Q1: OR = 1.68 (1.22–2.30)
p for trend = 0.002
Normal weight participants:
Q4 vs. Q1: OR = 3.17 (1.23–8.18)
Overweight/obese participants:
Q4 vs. Q1: OR = 1.56 (1.09–2.24)
Silver et al. 2011 [46] Type 2 diabetes: HbA1c ≥6.5 % or
self-reported use of diabetes
medication (insulin or blood
sugar-lowering pills)
BPA continuous (log-transformed) For a doubling in uBPA
concentration:
Age, age2, urinary creatinine as natural
splines with 4° of freedom, gender,
race-ethnicity, education,
household income, BMI, WC, smoking status2003/04: OR = 1.23 (1.07–1.41)
2005/06: OR = 1.06 (0.95–1.19)
2007/08: OR = 1.06 (0.91–1.23)
Pooled 2003/08: OR = 1.08 (1.02–
1.16)
Incident diabetes (1 publication)
Sun et al. 2014 [61] Type 2 diabetes: self-reported
diagnosis confirmed with one
of the ADA 1998 criteria: a)
elevated glucose concentration
and ≥1 symptom related to
diabetes; b) no symptoms but
elevated glucose concentrations
on 2 separate occasions; or c)
treatment with insulin or oral
hypoglycemic medication
BPA in quartiles (ng/mL): NHS cohort (older women): Age at urine sample collection, ethnicity,
fasting status, time of sample collection,
menopausal status, use of hormone
replacement therapy (NHSII
only), urinary creatinine levels, smoking
status, postmenopausal hormone use
(NHS only), oral contraceptive use (NHSII
only), physical activity, alcohol use, family
history of diabetes, history of
hypercholesterolemia or hypertension,
Alternative Health Eating Index score, BMI
NHS cohort / NHSII cohort Q2 vs. Q1: OR = 0.91 (0.56–1.48)
Q1: <1.0 / <1.3 Q3 vs. Q1: OR = 0.98 (0.60–1.61)
Q2: 1.0–1.5 / 1.3–2.0 Q4 vs. Q1: OR = 0.81 (0.48–1.38)
Q3: 1.5–2.7 / 2.0–3.5 p for trend = 0.45
Q4: >2.7 / >3.5
NHSII cohort (younger women):
Q2 vs. Q1: OR = 1.34 (0.70–2.27)
Q3 vs. Q1: OR = 1.91 (1.11–3.29)
Q4 vs. Q1: OR = 2.08 (1.17–3.69)
p for trend = 0.02
Prevalent prediabetes (1 publication)
Sabanayagam et al. 2013
[41]
Prediabetes: FPG = 100-125
mg/dL or 2-h glucose
concentration = 140–199
mg/dL or HbA1c = 5.7–6.4 %
(ADA guidelines)
BPA in tertiles (ng/mL): T1: <1.3;
T2: 1.3–3.2; T3: >3.2
T2 vs. T1: OR = 1.42 (1.14–1.76) Age, gender, race-ethnicity, education,
smoking, alcohol intake, BMI, physical
inactivity, mean arterial blood pressure,
C-reactive protein, total cholesterol/
HDL ratio
T3 vs. T1: OR = 1.34 (1.03–1.73)
p for trend = 0.02
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Table 2 Summary of results in studies used as primary data: diabetes, prediabetes and hyperglycemia (n = 12 publications) (Continued)
Stronger associations among women
and obese participants.
Women:
T2 vs. T1: OR = 1.36 (0.96–1.91)
T3 vs. T1: OR = 1.49 (1.00–2.22)
p for trend = 0.04
Obese:
T2 vs. T1: OR = 1.71 (1.05–2.80)
T3 vs. T1: OR = 1.65 (1.04–2.80)
p for trend = 0.04
Prevalent hyperglycemia (2 publications)
Beydoun et al.
2014 [34]
Hyperglycemia: FPG
≥100 mg/dL
BPA continuous (log-transformed) OR = 1.0 (0.9–1.2) Age, sex, race, education, marital status,
smoking status, physical activity, dietary
energy intake, urinary creatinine, survey
waveBPA in quartiles (ng/mL): Q1: 0.3 to
<1.0; Q2: 1.0 to <2.0; Q3: 2.0 to
<3.7; Q4: ≥3.7
Q2 vs. Q1: OR = 0.9 (0.52–1.42)
Q3 vs. Q1: OR = 1.2 (0.7–1.9)
Q4 vs. Q1: OR = 1.1 (0.6–1.9)
p for trend = 0.55
Ratio of BPA-to-creatinine continuous
(log-transformed)
OR = 1.0 (0.9–1.2)
Ratio of BPA-to-creatinine in quartiles:
Q1: 0.001 to <0.01; Q2: 0.01 to <0.02;
Q3: 0.02 to <0.03; Q4: ≥0.03
Q2 vs. Q1: OR = 1.1 (0.8–1.6)
Q3 vs. Q1: OR = 1.3 (0.8–1.9)
Q4 vs. Q1: OR = 1.2 (0.8–1.9)
p for trend = 0.30
Eng et al. 2013 [38] Abnormal glucose: FPG
≥100 mg/dL
BPA in quartiles (ng/mL) Age, gender, race/ethnicity, urine
creatinine, poverty-to-income ratio,
serum cotinine as a marker of smoking
status, soda consumption, BMI percentile
Q1: <1.3 Q2 vs. Q1: OR = 0.77 (0.33–1.78)
Q2: 1.3–2.6 Q3 vs. Q1: OR = 1.32 (0.57–3.04)
Q3: 2.6–4.9 Q4 vs. Q1: OR = 0.63 (0.22–1.82)
Q4: >4.9
ADA American Diabetes Association; ALT alanine aminotransferase; BMI body mass index; BPA bisphenol A; FPG fasting plasma glucose; HbA1c glycated hemoglobin; HDL high density lipoprotein; hsCRP high sensitivity
C-reactive protein; NHS Nurses' Health Study; OR odds ratio, SD standard deviation; T2D type 2 diabetes; TG triglycerides; uBPA urinary bisphenol A; WC waist circumference
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Table 3 Summary of results in studies used as primary data: indicators of anthropometry and adiposity (n = 16 publications)
Reference Outcomes & definitions used Urinary BPA categorisation Results Adjustment in model(s) used for review
In children
Prevalent overweight (4 publications)
Eng et al.
2013 [38]
Overweight: BMI ≥85th
percentile for age/gender
BPA in quartiles (ng/mL): Q1: <1.3;
Q2: 1.3–2.6; Q3: 2.6–4.9; Q4: >4.9
Q2 vs. Q1: OR = 1.00 (0.74–1.36) Age, gender, race/ethnicity, urine creatinine,
poverty-to-income ratio, serum cotinine as a
marker of smoking status, soda consumptionQ3 vs. Q1: OR = 1.17 (0.89–1.54)
Q4 vs. Q1: OR = 1.07 (0.80–1.44)
Harley et al.
2013 [64]
Overweight: BMI ≥85th
percentile at 5 and 9 years
of age
Ratio of BPA-to-creatinine level as
continuous (log2- transformed) at
5 years
OR = 1.07 (0.90–1.28) Maternal prepregnancy BMI, household
income, maternal education level, maternal
years of residence in the United States, child’s
environmental tobacco smoke exposure, soda
intake, fast food intake, and sweet
consumption
Ratio of BPA-to-creatinine level in
3 tertiles at 5 years (μg/g):
T2 vs. T1: OR = 0.80 (0.45–1.42)
T1: <LOD-2.4; T2: 2.4–4.5 μg/g;
T3: 4.6–349.8 μg/g
T3 vs. T1: OR = 1.36 (0.75–2.47)
Ratio of BPA-to-creatinine level as
continuous (log2- transformed) at
9 years
OR = 1.06 (0.85–1.33)
Ratio of BPA-to-creatinine level in
3 groups at 9 years (μg/g):
G2 vs. G1: OR = 3.08 (1.18–8.02)
G1: <LOD (<0.4); G2: detectable
< median (0.4–1.8); G3: detectable >
median (1.8–22.5)
G3 vs. G1: OR = 4.20 (1.60–11.02)
Li et al. 2013
[49]
Overweight: age- and
gender-specific weight
>90th percentile of the
underlying population
BPA in 2 classes (ng/mL): Low BPA
level: <2 (reference); high BPA
level: ≥2(2 mg/L is about the
median urine BPA level in the
U.S. population)
Girls Age, gender, school, residence, paternal and
maternal education and overweight, playing
video games, unbalanced diet, eating junk
food, vegetables or fruit, depression scores,
sports/activities
All: OR=1.29 (0.83–2.01)
Age 9-12: OR= 2.32 (1.15-4.65)
Age>12: OR= 0.90 (0.48-1.72)
Boys
All: OR=0.82 (0.55–1.23)
Age 9-12: OR= 0.71 (0.34-1.45)
Age>12: OR= 0.87 (0.52-1.45)
Trasande
et al. 2012
[47]
Overweight: BMI z-score
≥1.036 (85th percentile for
age/sex)
BPA continuous (log-transformed) OR = 1.04 (0.92–1.18) Sex, caloric intake, television watching, poverty
to income ratio, parental education, serum
cotinine level, urinary creatinine level, age,
race/ethnicity categories
BPA in quartiles (ng/mL): Q1: ≤1.5;
Q2: 1.5–2.7; Q3: 2.8–5.5; Q4: >5.6
Q2 vs. Q1: OR = 1.26 (0.96–1.64)
Q3 vs. Q1: OR = 1.28 (0.98–1.66)
Q4 vs. Q1: OR = 1.26 (0.86–1.82)
Prevalent obesity (3 publications)
Bhandari et al.
2013 [35]
Obesity: BMI ≥ 95th percentile
for age/gender
BPA continuous (log-transformed) OR = 1.25 (1.09–1.43) Age, sex, race/ethnicity, education, moderate
activity, urinary creatinine, serum cotinine
BPA in quartiles (ng/mL): Q1: <1.5;
Q2: 1.5–2.7; Q3: 2.8–5.4; Q4: >5.4
Q2 vs. Q1: OR = 2.35 (1.56–3.53)
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Table 3 Summary of results in studies used as primary data: indicators of anthropometry and adiposity (n = 16 publications) (Continued)
Q3 vs. Q1: OR = 1.78 (1.13–2.79)
Q4 vs. Q1: OR = 2.55 (1.65–3.95)
p for trend = 0.002
Stratified analyses by sex (p for
interaction = 0.07): association
of strong magnitude and
statistically significant among
boys
Eng et al.
2013 [38]
Obesity: BMI ≥95th percentile
for age/gender
BPA in quartiles (ng/mL): Q1: <1.3;
Q2: 1.3–2.6; Q3: 2.6–4.9; Q4: >4.9
Q2 vs. Q1: OR = 1.73 (1.16–2.58) Age, gender, race/ethnicity, urine creatinine,
poverty-to-income ratio, serum cotinine as a
marker of smoking status, soda consumptionQ3 vs. Q1: OR = 1.63 (1.08–2.46)
Q4 vs. Q1: OR = 2.05 (1.38–3.04)
Trasande
et al. 2012
[47]
Obesity: BMI z-score ≥1.64
(95th percentile for age/sex)
BPA continuous (log-transformed) Continuous: OR = 1.24 (1.08–1.44) Sex, caloric intake, television watching,
poverty-to-income ratio, parental education,
serum cotinine level, urinary creatinine level,
age, race/ethnicity categories
BPA in quartiles (ng/mL): Q1: ≤1.5;
Q2: 1.5–2.7; Q3: 2.8–5.5; Q4: >5.6
Q2 vs. Q1: OR = 2.24 (1.54–3.24)
Q3 vs. Q1: OR = 2.08 (1.46–2.96)
Q4 vs. Q1: OR = 2.57 (1.72–3.83)
Prevalent elevated waist circumference
Eng et al.
2013 [38]
Abnormal WC: WC ≥90th
percentile for age/gender
Abnormal WC-to-height ratio:
WC-to-height ratio ≥0.5
BPA in quartiles (ng/mL): Q1: <1.3;
Q2: 1.3–2.6; Q3: 2.6–4.9; Q4: >4.9
Abnormal WC Age, gender, race/ethnicity, urine creatinine,
poverty-to-income ratio, serum cotinine as a
marker of smoking status, soda consumptionQ2 vs. Q1: OR = 1.33 (0.90–1.97)
Q3 vs. Q1: OR = 1.16 (0.75–1.81)
Q4 vs. Q1: OR = 1.40 (0.91–2.15)
Abnormal WC-to-height ratio
Q2 vs. Q1: OR = 1.37 (0.97–1.92)
Q3 vs. Q1: OR = 1.41 (1.07–1.87)
Q4 vs. Q1: OR = 1.56 (1.11–2.17)
Other
Braun et al.
2014 [63]
Change in BMI z-score between
2 and 5 years of age, as
continuous
Ratio of BPA-to-creatinine
continuous (log10-transformed)
Per 10-fold increase:β = −0.2
(−0.6, 0.1)
Maternal race, marital status, parity, age at
delivery, household income, education,
employment, insurance, BMI at 16 weeks of
pregnancy, depressive symptoms at baseline,
prenatal serum cotinine
Ratio of BPA-to-creatinine in
tertiles (μg/g creatinine):
T2 vs. T1: β = 0.0 (−0.3, 0.3)
T1: 2.1–11; T2: 11–20; T3: 20–314 T3 vs. T1: β = −0.2 (−0.5, 0.1)
Eng et al.
2013 [38]
Prevalent abnormal body fat:
body fat ≥85th percentile for
age/gender
BPA in quartiles (ng/mL): Q1: <1.3;
Q2: 1.3–2.6; Q3: 2.6–4.9; Q4: >4.9
Q2 vs. Q1: OR = 4.85 (0.80–21.4) Age, gender, race/ethnicity, urine creatinine,
poverty-to-income ratio, serum cotinine as a
marker of smoking status, soda consumptionQ3 vs. Q1: OR = 5.36 (0.71–43.3)
Q4 vs. Q1: OR = 2.10 (0.24–17.8)
Harley et al.
2013 [64]
Incident overweight: BMI
≥85th percentile at 9 years of age
Ratio of BPA-to-creatinine level at
5 years as continuous (log2-
transformed)
OR = 1.02 (0.84–1.23) Maternal prepregnancy BMI, household
income, maternal education level, maternal
years of residence in the United States, child’s
environmental tobacco smoke exposure, soda
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Table 3 Summary of results in studies used as primary data: indicators of anthropometry and adiposity (n = 16 publications) (Continued)
intake, fast food intake, and sweet
consumption at age 5 years
Ratio of BPA-to-creatinine level at
5 years in tertiles (μg/g):
T2 vs. T1: 0.91 (0.48–1.73)
T1: <LOD-2.4; T2: 2.4–4.5;
T3: 4.6–349.8
T3 vs. T1: 1.28 (0.65–2.51)
Wang et al.
2012b [50]
Prevalent BMI as continuous (kg/m2) BPA continuous (log-transformed
and corrected for specific gravity)
β = 0.017 (0.002–0.032) Age, sex
Wells et al.
2013 [48]
Prevalent waist-to-height
ratio as continuous
BPA in quartiles (ng/mL): Q1: <1.2;
Q2: 1.2–2.6; Q3: 2.6–5.1; Q4: >5.1
Change in waist-to-height ratio: Urinary creatinine, age, sex, race/ethnicity,
education, smoking status based on serum
cotinine, caloric intakeQ2 vs. Q1: β = 0.011 (0.001–0.020)
Q3 vs. Q1: β = 0.010 (0.001–0.019)
Q4 vs. Q1: β = 0.016 (0.007–0.026)
Significant associations among
boys but not girls.
In adults
Prevalent overweight (3 publications)
Carwile &
Michels 2011
[36]
Overweight: 25 ≤ BMI <
30 kg/m2 (reference: BMI
<25 kg/m2)
BPA in quartiles (ng/mL): Q1: ≤1.1;
Q2: 1.2–2.3; Q3: 2.4–4.6; Q4: ≥4.7
Q2 vs. Q1: OR = 1.66 (1.21–2.27) Age, gender, race/ethnicity, education,
smoking status, urinary creatinine
Q3 vs. Q1: OR = 1.26 (0.85–1.87)
Q4 vs. Q1: OR = 1.31 (0.80–2.14)
Kim et al.
2011 [55]
Overweight: BMI = 23-24.9
kg/m2, according to the WHO
definitions for the Asian
populations (reference: BMI
<18.5 kg/m2)
BPA continuous (log-transformed) Adjusted proportional change
(95 % CI) = 1.01 (0.78–1.31)
Age, gender, education, income, cigarette
smoking status, place of residence, urinary
creatinine
Wang et al.
2012a [52]
Generalized overweight: 24
≤ BMI < 28 kg/m2, according
to Chinese criteria (reference =
BMI <24 kg/m2)
BPA in quartiles (ng/mL): Q1: ≤0.47;
Q2: 0.48–0.81; Q3: 0.82–1.43;
Q4: >1.43
Q2 vs. Q1: OR = 1.23 (0.97–1.57) Age, sex, urinary creatinine, smoking, alcohol
drinking, education levels, systolic blood
pressure, HDL cholesterol, LDL cholesterol,
total cholesterol, TG, hsCRP, fasting plasma
glucose, fasting serum insulin, serum ALT
and GGT
Q3 vs. Q1: OR = 1.28 (1.01–1.63)
Q4 vs. Q1: OR = 1.24 (0.97–1.59)
Prevalent obesity (4 publications)
Carwile &
Michels 2011
[36]
Obesity: BMI ≥30 kg/m2
(reference: BMI <25 kg/m2)
BPA in quartiles (ng/mL): Q1: ≤1.1;
Q2: 1.2–2.3; Q3: 2.4–4.6; Q4: ≥4.7
Q2 vs. Q1: OR = 1.85 (1.22–2.79) Age, gender, race/ethnicity, education,
smoking status, urinary creatinine
Q3 vs. Q1: OR = 1.60 (1.05–2.44)
Q4 vs. Q1: OR = 1.76 (1.06–2.94)
Kim et al.
2011 [55]
Obesity: BMI ≥25 kg/m2,
according to the WHO
definitions for the Asian
populations (reference =
BMI <18.5 kg/m2)
BPA continuous (log-transformed) Adjusted proportional change
(95 % CI) = 0.96 (0.75–1.23)
Age, gender, education, income, cigarette
smoking status, place of residence, urinary
creatinine
Shankar et al.
2012 [44]
Obesity: BMI ≥30 kg/m2
(reference = BMI <30 kg/m2)
BPA in quartiles (ng/mL): Q1: <1.10;
Q2: 1.10–2.10; Q3: 2.11–4.20; Q4: >4.20
Q2 vs. Q1: OR = 1.40 (1.10–1.76) Age, gender, race/ethnicity, education
categories, smoking, alcohol consumption,
Q3 vs. Q1: OR = 1.59 (1.25–2.02)
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Table 3 Summary of results in studies used as primary data: indicators of anthropometry and adiposity (n = 16 publications) (Continued)
physical inactivity, diabetes, hypertension,
total cholesterol
Q4 vs. Q1: OR = 1.69 (1.30–2.20)
p for trend < 0.0001
Associations still significant in
analyses stratified by sex.
Wang et al.
2012a [52]
Generalized obesity: BMI ≥28
kg/m2, according to Chinese
criteria (reference: BMI <28
kg/m2)
BPA in quartiles (ng/mL): Q1: ≤0.47;
Q2: 0.48–0.81; Q3: 0.82–1.43;
Q4: >1.43
Q2 vs. Q1: OR = 1.14 (0.87–1.50) Age, sex, urinary creatinine, smoking, alcohol
drinking, education levels, systolic blood
pressure, HDL cholesterol, LDL cholesterol,
total cholesterol, TG, hsCRP, fasting plasma
glucose, fasting serum insulin, serum ALT
and GGT
Q3 vs. Q1: OR = 1.19 (0.90–1.57)
Q4 vs. Q1: OR = 1.50 (1.15–1.97)
Prevalent elevated waist circumference
(4 publications)
Carwile &
Michels 2011
[36]
Elevated WC: WC ≥102 cm
in men and WC ≥88 cm in
women
BPA in quartiles (ng/mL): Q1: ≤1.1;
Q2: 1.2–2.3; Q3: 2.4–4.6; Q4: ≥4.7
Q2 vs. Q1: OR = 1.62 (1.11–2.36) Age, gender, race/ethnicity, education,
smoking status, urinary creatinine
Q3 vs. Q1: OR = 1.39 (1.02–1.90)
Q4 vs. Q4: OR = 1.58 (1.03–2.42)
Ko et al. 2014
[57]
Abdominal obesity: WC
≥90 cm in men and WC
≥85 cm in women
BPA in quartiles (μg/mL)
Q1: <0.853; Q2: 0.853–1.407;
Q3: 1.407–2.594; Q4: >2.594
Q2 vs. Q1: 1.117 (0.757–1.649) Age, sex, urinary creatinine, education,
income, alcohol consumption, smoking
statusQ3 vs. Q1: 1.337 (0.908–1.967)
Q4 vs. Q1: 1.938 (1.314–2.857)
p for trend = 0.01
Shankar et al.
2012 [44]
Abdominal obesity: WC
≥102 cm in men and WC
≥88 cm in women
BPA in quartiles (ng/mL):
Q1: <1.10; Q2: 1.10–2.10; Q3: 2.11–
4.20; Q4: >4.20
Q2 vs. Q1: OR = 1.63 (1.20–2.22) Age, gender, race/ethnicity, education
categories, smoking, alcohol consumption,
physical inactivity, diabetes, hypertension,
total cholesterol
Q3 vs. Q1: OR = 1.66 (1.28–2.14)
Q4 vs. Q1: OR = 1.59 (1.21–2.09)
p for trend = 0.0009
Associations still significant in
analyses stratified by sex
Wang et al.
2012a [52]
Abdominal obesity: WC
≥90 cm in men and WC
≥85 cm in women
BPA in quartiles (ng/mL): Q1: ≤0.47;
Q2: 0.48–0.81; Q3: 0.82–1.43;
Q4: >1.43
Q2 vs. Q1: OR = 1.26 (1.02–1.57) Age, sex, urinary creatinine, smoking, alcohol
drinking, education levels, systolic blood
pressure, HDL cholesterol, LDL cholesterol,
total cholesterol, TG, hsCRP, fasting plasma
glucose, fasting serum insulin, serum ALT
and GGT
Q3 vs. Q1: OR = 1.28 (1.03–1.59)
Q4 vs. Q1: OR = 1.28 (1.03–1.60)
Other
Galloway
et al. 2010
[58]
Prevalent WC as continuous
Prevalent weight as continuous
Daily BPA excretion (μg/day) as a
continuous variable
WC: β = 0.0062 (0.0016–0.0108) Age, sex, study site
Weight: β = 0.0064 (0.0023–0.0104)
Kim et al.
2011 [55]
Prevalent normal weight:
BMI = 18.5–22.9 kg/m2,
according to the WHO
definitions for the Asian
BPA continuous (log-transformed) Adjusted proportional change
(95 % CI) = 0.92 (0.72–1.17)
Age, gender, education, income, cigarette
smoking status, place of residence, urinary
creatinine
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Table 3 Summary of results in studies used as primary data: indicators of anthropometry and adiposity (n = 16 publications) (Continued)
populations (reference: BMI
< 18.5 kg/m2)
Song et al.
2014 [62]
Weight change rate (WCR)
during follow-up (kg/year)
BPA in quartiles (nmol/L): Age at baseline, urinary creatinine
concentration, cohort origin, menopausal
status, smoking, alcohol consumption,
physical activity, alternative healthy eating
index, total energy intake
Q1: median (IQR) = 3.6 (2.6–4.5) Q2 vs. Q1: WCR = 0.15 (0.00–0.31)
Q2: median (IQR) = 6.4 (5.8–7.3) Q3 vs. Q1: WCR = 0.18 (0.03–0.34)
Q3: median (IQR) = 10.5 (9.0–12.1) Q4 vs. Q1: WCR = 0.23 (0.07–0.38)
Q4: median (IQR) = 21.9 (16.8–35.7) p for trend = 0.02
Zhao et al.
2012 [53]
Fat mass, fat-free mass, body weight, BMI,
WC, hip circumference, waist-hip ratio (all
variables as continuous)
BPA continuous Fat mass: r = 0.35 (p < 0.001) Age
Fat-free mass: r = 0.186 (p = 0.009)
Body weight: r = 0.24 (p = 0.001)
BMI: r = 0.298 (p < 0.001)
WC: r = 0.296 (p < 0.001)
Hip circumference: r = 0.27
(p < 0.001)
Waist-hip ratio: r = 0.149
(p = 0.035)
With additional adjustment for age
and BMI, BPA was still significantly
associated with fat mass (r = 0.193,
p = 0.006) but not with fat-free mass.
ALT alanine aminotransferase; BMI body mass index; BPA bisphenol A; GGT gamma glutamyltransferase; HDL high density lipoprotein; hsCRP high sensitivity C-reactive protein; IQR interquartile range; LDL low density
lipoprotein; LOD limit of detection; OR odds ratio; TG triglycerides; WC waist circumference; WCR weight change rate
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Table 4 Summary of results in studies used as primary data: cardiovascular disease and hypertension (n = 9 publications)
Reference Outcomes & definitions used Urinary BPA categorisation Results Adjustment in model(s) used for review
Prevalent CVD (5 publications)
Casey &
Neidell 2013
[37]
CHD: self-report of doctor diagnosis BPA continuous (not log-
transformed)
Per SD increase: Age, sex, urinary creatinine concentration, race/ethnicity,
income, smoking, body mass index, waist circumference,
veteran/military status, citizenship status, marital status,
household size, pregnancy status, language at subject
interview, health insurance coverage, employment status
in the prior week, consumption of bottled water in the
past 24 h, consumption of alcohol, annual consumption
of tuna fish, presence of emotional support in one’s life,
being on a diet, using a water treatment device, access
to a routine source of health care, vaccinated for Hepatitis
A or B, consumption of dietary supplements (vitamins or
minerals), inability to purchase balanced meals on a
consistent basis + survey cycle for pooled analyses
2003/04: OR = 1.824 (1.288–2.583)
2005/06: OR = 1.267 (1.041–1.542)
2007/08: OR = 1.123 (0.854–1.476)
Pooled 2003/08: OR = 1.136 (1.014–1.273)
BPA continuous (log-transformed) Per 10-fold increase:
2003/04: OR = 1.584 (1.066–2.354)
2005/06: OR = 1.178 (0.765–1.815)
2007/08: OR = 1.649 (1.025–2.654)
Pooled 2003/08: OR = 1.280 (0.993–1.649)
BPA in quartiles (ng/mL):
Q1: <1.2; Q2: 1.2–2.2; Q3: 2.3–4.2;
Q4: >4.2
Pooled 2003/08:
Q2 vs. Q1: 0.520 (0.250–1.084)
Q3 vs. Q1: 1.006 (0.508–1.994)
Q4 vs. Q1: 1.520 (0.774–2.987)
Lakind et al.
2012 [33]
CHD: self-report of doctor diagnosis
Heart attack: self-report of doctor
diagnosis
BPA continuous CHD, per unit increase: Age, gender, ethnicity, education, income, smoking, heavy
drinking, BMI, waist circumference, energy intake, family
history of heart attack, hypertension, sedentary activity,
total cholesterol, urinary creatinine. Pooled 2003/10 models
were further adjusted for survey cycle, but were not
adjusted for energy intake and sedentary activity.
2003/04: OR = 1.03 (0.978–1.09)
2005/06: OR = 1.02 (0.996–1.04)
2007/08: OR = 0.996 (0.951–1.04)
2009/10: OR = 1.00 (0.998–1.01)
Pooled 2003/10: OR = 1.004 (0.998–1.009)
Heart attack, per unit increase:
2003/04: OR = 1.04 (0.996–1.09)
2005/06: OR = 1.02 (0.996–1.04)
2007/08: OR = 0.987 (0.941–1.04)
2009/10: OR = 1.00 (0.999–1.01)
Pooled 2003/10: OR = 1.002 (0.998–1.007)
Lang et al.
2008 [39]
Heart attack, angina, CHD, CVD (any
diagnoses of MI, angina or CHD),
stroke; all self-reported doctor
diagnoses
BPA continuous Per SD increase: Age, gender, race/ethnicity, education, income, BMI, WC,
smoking status, urinary creatinine
Heart attack: OR = 1.40 (1.11–1.78),
Angina: OR = 1.28 (1.09–1.50)
CHD: OR = 1.63 (1.18–2.26)
CVD: OR = 1.39 (1.18–1.63)
Stroke: OR = 0.97 (0.74–1.27)
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Melzer et al.
2010 [40]
MI, angina, CHD, CVD (any
diagnoses of MI, angina or CHD);
all self-reported doctor diagnoses
BPA continuous MI, per SD increase: Age, gender, ethnicity, education, income, BMI, WC,
smoking status, urinary creatinine
2003/04: OR = 1.40 (1.07–1.84)
2005/06: OR = 1.39 (1.00–1.94)
Pooled 2003/06: OR = 1.32 (1.15–1.52)
Angina, per SD increase:
2003/04: OR = 1.27 (1.06–1.54)
2005/06: OR = 1.16 (0.88–1.53)
Pooled 2003/06: OR = 1.24 (1.07-1.43)
CHD, per SD increase:
2003/04: OR = 1.60 (1.11–2.32)
2005/06: OR = 1.33 (1.01–1.75)
Pooled 2003/06: OR = 1.42 (1.17–1.72)
CVD, per SD increase:
2003/04: OR = 1.34 (1.10–1.66)
2005/06: OR = 1.18 (0.88–1.59)
Pooled 2003/06: OR = 1.26 (1.11–1.44)
Melzer et al.
2012b [59]
CAD: no, intermediate, severe
(assessed by angiography)
BPA continuous Per SD increase: Age, sex, BMI category, occupational social class, diabetes
status
Intermediate vs. no CAD: OR = 1.69 (0.98–2.94)
Severe vs. no CAD: OR = 1.43 (1.03–1.98)
Incident CVD (1 publication)
Melzer et al.
2012a [60]
Incident CAD during follow-up:
recorded hospital admission and/or
died with CAD as underlying cause
BPA continuous Per SD increase: Age, sex, urinary creatinine, education level, occupational
group, BMI, cigarette smoking, average of the 2 systolic BP
readings, total cholesterol, LDL cholesterol, HDL cholesterol,
TG, level of physical activity
OR = 1.11 (1.00–1.23)
Prevalent hypertension (3 studies)
Bae et al. 2012
[54]
Hypertension: systolic BP ≥140 mm
Hg or diastolic BP ≥90 mm Hg
Ratio of BPA-to-creatinine in
quartiles (μg/g creatinine): Q1:
<0.37; Q2: 0.37–0.73; Q3: 0.73–1.33;
Q4: >1.33
All participants: Age, sex, height, weight, date of examination, mean fasting
blood glucose, smoking status, current consumption of
alcoholQ2 vs. Q1: OR = 1.21 (0.80–1.84)
Q3 vs. Q1: OR = 1.16 (0.78–1.72)
Q4 vs. Q1: OR = 1.27 (0.85–1.88)
Stratification by gender: non-significant results
in males and females.
Significant associations in participants without
previous history of hypertension
Q2 vs. Q1: OR = 2.23 (1.21–4.12)
Q3 vs. Q1: OR = 1.79 (1.01–3.17)
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Table 4 Summary of results in studies used as primary data: cardiovascular disease and hypertension (n = 9 publications) (Continued)
Q4 vs. Q1: OR = 2.35 (1.33–4.17)
Shankar &
Teppala 2012
[43]
Hypertension: current blood-
pressure-reducing medication use
and/or systolic BP >140 mmHg and/
or diastolic BP >90 mm Hg
BPA continuous (log-transformed) OR = 1.11 (1.01–1.22) Age, sex, race/ethnicity, education categories, smoking,
alcohol intake, BMI, diabetes, total cholesterol
BPA in tertiles (ng/mL): T1: <1.5;
T2: 1.5–4.0; T3: >4.0
T2 vs. T1: OR = 1.11 (0.71–1.74)
T3 vs. T1: OR = 1.50 (1.12–2.00)
p for trend = 0.007
Shiue et al.
2014 [45]
High BP: systolic BP ≥140 mmHg
and diastolic BP ≥90 mmHg
BPA continuous (log-transformed) Adjusted model: OR = 1.14 (1.00–1.30) Urinary creatinine, age at examination, sex, ethnicity, BMI
Weighted model (additionally adjusted for
subsample weighting): OR = 1.12 (0.93–1.35)
BMI body mass index; BP blood pressure; BPA bisphenol A; CAD coronary artery disease; CHD coronary heart disease; CVD cardiovascular disease; HDL high density lipoprotein; LDL low density lipoprotein; MI
myocardial infraction; OR odds ratio; SD: standard deviation; TG triglycerides; WC waist circumference
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creatinine as the exposure variable [34, 54, 63, 64]. All
but 4 adult studies adjusted for smoking [32, 51, 53, 58],
and in the studies of children, smoking exposure was
assessed by urine cotinine [35, 38, 47, 48, 63, 64] or
questionnaire [64]. For the studies that investigated glu-
cose, CVD or hypertension as the outcome, all except one
[34] adjusted for WC [33, 37, 40, 46, 51], body mass index
(BMI) [32, 33, 37–41, 43, 45, 46, 56, 59–61] or both height
and weight [54].
All studies except 8 [32, 45, 50, 53, 54, 58, 61, 62] ad-
justed their statistical models for socioeconomic vari-
ables (e.g., education, income, occupation). All U.S.
studies were adjusted for race/ethnicity.
Ten out of 33 studies (30 %) adjusted their models for diet-
ary intake such as total energy intake [33, 34, 47, 48, 62],
sugar-sweetened soda consumption [38, 64], ‘healthy’ food
consumption [49, 61, 62] or unbalanced diet (e.g., fast food
or sweet consumption) [49, 64]. Casey & Neidell adjusted
for potential BPA sources including consumption of bottled
water and canned tuna [37].
Quality of individual studies
Detailed results of the quality assessment of individual stud-
ies according to our scoring system are reported in the
Additional file 1: Table S4. In summary, there were 4 (12 %)
studies scored as ‘high-quality’, 27 (82 %) scored as
‘medium-quality’ and 2 (6 %) scored as ‘low-quality’. All
‘high-quality’ studies were longitudinal [60, 61, 63, 64]. Re-
sults reported in these ‘high-quality’ studies were mixed or
significant. Significant and non-significant results were also
reported in ‘medium quality’ and ‘low quality’ studies.
Diabetes and hyperglycemia
Diabetes
Eight cross-sectional studies reported on the relation be-
tween uBPA and diabetes [32, 37, 39, 40, 42, 46, 51, 56],
and seven supported a positive association (Table 2).
In NHANES, a positive association between uBPA
concentrations and self-reported diabetes was reported
in the NHANES 2003–04 cycle (OR = 1.39, 95 % CI:
1.21–1.60) [39], but results did not reach significance in
the NHANES 2005–06 [40] nor 2007–08 [46] popula-
tions. Indeed, Casey & Neidell found significant interac-
tions between uBPA and NHANES cycle [37]. Using 3
different statistical models within NHANES cycles from
2003–04 to 2007–08, they reported a positive association
in only the 2003–04 cycle.
In a pooled NHANES 2003–08 dataset, Shankar &
Teppala used a definition of diabetes based on fasting
glucose level, HbA1c level, non-fasting glucose level and
self-reported current use of diabetes medication, and
found a significant positive linear trend across uBPA
quartiles (p = 0.002) [42]. Although both statisticallysignificant, the OR for quartile 4 (Q4) compared to
quartile 1 (Q1) was about two times higher in normal
weight participants (OR = 3.17) than in overweight/obese
participants (OR = 1.56).
No significant association was shown in a Korean cross-
sectional study [56]. In a Chinese cross-sectional study, the
adjusted OR for type 2 diabetes was statistically significant
in the second (OR= 1.30, 95 % CI: 1.03–1.64) and fourth
(OR = 1.37, 95 % CI: 1.08–1.74) uBPA quartiles, but not in
the third uBPA quartile (OR = 1.09, 95 % CI: 0.86–1.39),
compared to the first quartile [51]. Among 131 Iranian par-
ticipants, Ahmadkhaniha et al. reported a significant ad-
justed OR of 57 for type 2 diabetes when comparing the
participants with uBPA above the median to those with
uBPA below the median [32].
One prospective study, among U.S. women from the
NHS and the NHSII cohorts, has been published [61].
While a positive association between uBPA and incident
diabetes was reported among middle-aged women from
the NHSII study (OR = 2.08, 95 % CI: 1.17–3.69, for Q4
vs. Q1), no significant results were found in older women
from the NHS study (OR = 0.81, 95 % CI: 0.48–1.38, for
Q4 vs. Q1).
Prediabetes and hyperglycemia
In one cross-sectional study, there was a positive associ-
ation between uBPA tertiles and prediabetes, with asso-
ciations stronger in women and obese subjects [41].
Two cross-sectional studies reported the relation be-
tween uBPA and elevated fasting blood glucose, one in
children [38], one in adults [34]; neither reported a sig-
nificant association.
Meta-analysis
For prevalent diabetes, the inclusion of the study by
Ahmadkhaniha et al. [32] led to highly significant het-
erogeneity (p < 10−5 and I2 = 94 %); consequently we ex-
cluded this study from the meta-analysis. Finally, three
cross-sectional studies, all examining uBPA levels in
quartiles, were included in the meta-analysis (n = 9291)
[37, 51, 56]. Pooled ORs (95 % CI) were 1.33 (1.10–
1.61), 1.18 (0.97–1.44) and 1.47 (1.21–1.80) in the sec-
ond, third, and fourth uBPA quartiles compared to the
first uBPA quartile. No significant heterogeneity was ob-
served (p = 0.88, 0.41 and 0.55 respectively, I2 = 0 %). We
were unable to conduct a meta-analysis for the other
outcomes due to insufficient numbers of studies.
Anthropometry and adiposity
The relationships between uBPA and measures of an-
thropometry (e.g., weight, overweight, obesity) or adipos-
ity (e.g., fat mass) were investigated in 16 studies,
including 8 studies conducted in children (Table 3).
Table 5 Pooled OR estimates for diabetes, overweight, obesity,
elevated waist circumference and hypertension comparing
extreme categories of urinary BPA levels (the highest vs. the
lowest): random effect models
Outcome Number
of
studies
Pooled ORa
(95 % CI)
Heterogeneity
p-value I2 (%)
Prevalent diabetes 3 1.47 (1.21–1.80) 0.55 0
Prevalent overweight
Total 5 1.21 (0.98–1.50) 0.09 45
Children only 3 1.24 (0.88–1.75) 0.03 62
Adults only 2 1.25 (1.01–1.56) 0.84 0
Prevalent obesity
Total 3 1.67 (1.41–1.98) 0.44 0
Adults only 2 1.60 (1.32–1.93) 0.54 0
Prevalent elevated WC
Total 4 1.48 (1.25–1.76) 0.28 21
Adults only 3 1.52 (1.21–1.90) 0.15 47
Prevalent hypertension 2 1.41 (1.12–1.79) 0.50 0
BPA bisphenol A; CI, confidence interval; OR odds ratio; WC
waist circumference
aUsing ORs comparing extreme categories of urinary BPA levels (the highest
vs. the lowest) summarized in Tables 2, 3 and 4
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A positive cross-sectional association between uBPA and
overweight was reported in 2 studies [49, 64], whereas 5
publications reported no significant associations with over-
weight [36, 38, 47, 52, 55]. In the only longitudinal study,
uBPA concentrations at age 5 were not associated with
overweight at age 9 [64]. All but one study found a signifi-
cant positive cross-sectional association between higher
uBPA concentrations and obesity [35, 38, 44, 47, 52, 55],
with ORs ranging from 1.50 to 2.57 for Q4 vs. Q1.
Waist circumference
The four cross-sectional studies examining the relationship
between uBPA and prevalent abdominal obesity in adults
showed significant positive results [36, 44, 52, 57]. Eng et al.
reported that in children, higher uBPA concentrations were
significantly associated with elevated WC-to-height ratio
(WHR), but not with elevated WC [38].
Three studies considered WC or WHR as a continu-
ous variable. One showed a positive linear association
between daily BPA excretion and WC [58] and another,
in women, reported a significant positive correlation be-
tween uBPA concentrations and WC [53]. The only
study in children found a statistically significant positive
association between uBPA and WHR [48].
Weight and BMI
Three cross-sectional studies examined the association be-
tween uBPA and weight [58] or BMI [50, 53] as continu-
ous variables. Both Chinese studies by Wang et al. [50]
and Zhao et al. [53] reported significant positive associa-
tions between uBPA and BMI. Galloway et al. [58] showed
that daily BPA excretion was significantly and positively
associated with BMI and weight in Italian adults.
Among the prospective studies, one reported that early
childhood uBPA concentrations were associated with a
modest and non-significant reduction in child BMI be-
tween 2 and 5 years of age [63], whereas the other found
that higher uBPA concentrations were significantly asso-
ciated with modestly faster weight gain in women [62].
Adiposity
In Chinese healthy premenopausal women, fat mass was
significantly correlated with uBPA when adjusting for
age [53]. In pooled NHANES 2003–10, abnormal body
fat in children was not associated with uBPA concentra-
tions in quartiles [38].
Meta-analysis
We included 5 cross-sectional studies for overweight
[36, 38, 49, 52, 64], including 2 in adults, 3 cross-
sectional studies for obesity [38, 44, 52], including 2 in
adults, and 4 cross-sectional studies for elevated WC
[38, 44, 52, 57], including 3 in adults.Higher BPA exposure was significantly associated with
obesity and elevated WC, and no significant heterogen-
eity between studies was found (Table 5). There was evi-
dence for overweight only in adults.Cardiovascular disease and hypertension
Cardiovascular disease
Four of the five cross-sectional studies reported a posi-
tive linear association between uBPA and CVD (Table 4).
An increased risk of self-reported CVD (myocardial in-
farction, angina, or coronary heart disease [CHD]: alone
or combined) was associated with increased concentra-
tion of uBPA (OR = 1.39, 95 % CI: 1.18–1.63), but no in-
creased risk of stroke (OR = 0.97, 95 % CI: 0.74–1.27) in
NHANES 2003–04 [39]. Melzer et al. then reported
similar associations when including NHANES 2005–06
data [40]. LaKind et al. examined NHANES data from
2003–04 to 2009–10 in adults aged ≥20 years, and found
no significant associations between self-reported CHD,
heart attack and uBPA as a continuous variable in either
separate or pooled populations [33]. Casey & Neidell re-
ported significant positive associations between uBPA
and CHD in NHANES 2003–04 but results were not
consistent in the subsequent 2005/06 and 2007/08 cycles
[37]. Melzer et al. studied coronary artery disease (CAD)
severity assessed by angiography [59]. Compared to par-
ticipants without CAD (n = 120), uBPA concentrations –
per standard deviation (SD) increase – were significantly
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n = 385), and near significantly associated with intermediate
CAD (OR= 1.69, 95 % CI: 0.98–2.94; n = 86).
The only prospective study, a nested case–control
study within the EPIC-Norfolk cohort, reported a posi-
tive association between uBPA concentrations and inci-
dence of CAD up to 10 years after BPA measurement,
with a significant increase in risk of CAD per SD in-
crease in uBPA: OR = 1.11, 95 % CI = 1.00-1.23 [60].
Hypertension
Three cross-sectional studies examined the association be-
tween uBPA and hypertension (Table 4). Both Shankar &
Teppala (using NHANES 2003–04 data) [43] and Shiue
et al. (NHANES 2009–10) [45] showed a positive associ-
ation between uBPA and hypertension. Bae et al. reported a
positive but non-significant association between uBPA and
hypertension (OR = 1.27, 95 % CI: 0.85–1.88 for Q4 vs. Q1)
in an elderly Korean population, and the association
reached significance when the analyses were restricted to
participants without a previous history of hypertension
(OR = 2.35, 95 % CI: 1.33–4.17) [54].
Meta-analysis
Meta-analysis for the CVD and uBPA data was not pos-
sible owing to different study designs and use of overlap-
ping NHANES data. For hypertension, we included two
cross-sectional studies and the pooled OR was statisti-
cally significant (Table 5).
Discussion
Summary of evidence
Our analysis presents summarized evidence of BPA ex-
posure and its associations with chronic cardiometabolic
disorders including glucose abnormalities, measures of
overweight/obesity, CVD and hypertension in humans.
Of the 33 epidemiological studies included, results
were generally consistent across cross-sectional studies,
with positive associations between uBPA concentrations
and diabetes, general obesity, abdominal obesity, CVD
and hypertension suggested in 7/8, 6/7, 5/5, 4/5 and 2/3
publications respectively. We were able to conduct
outcome-specific meta-analysis including 12 independ-
ent studies. While a risk of bias cannot be excluded, the
results indicate positive cross-sectional associations be-
tween uBPA concentrations and diabetes, general obes-
ity, abdominal obesity and hypertension. Results were
significant for overweight in adults but not in children.
We were unable to examine uBPA and CVD in meta-
analysis due to overlapping data and/or heterogeneity
among studies (in terms of study design and definition
of outcome).
Among the 5 prospective studies included in this re-
view, 3 showed that uBPA levels were positivelyassociated with incident type 2 diabetes and CAD, and
weight gain. While these first prospective results seem
to corroborate findings from cross-sectional studies,
more prospective data are needed to make the evidence
more robust.
Strengths and limitations of the current review
In recent years, there has been a rapid increase in publi-
cations examining the possible relationship between
BPA exposure and cardiometabolic health. A systematic
review of the epidemiological evidence linking BPA with
indicators of obesity, glucose metabolism and CVD, was
published by LaKind et al. in 2014 [33]. Further to their
results, we have been able to include 11 further publica-
tions into this review. We have also calculated pooled
ORs for diabetes, overweight, general/abdominal obesity,
and hypertension. In their systematic review, LaKind
et al. concluded that meta-analysis was not feasible due
to the heterogeneity across studies. Nonetheless we were
able to identify small but significant groups of cross-
sectional studies similar enough to be included in a
meta-analysis. However it should be noted that studies
included in the meta-analyses can differ with regard to
some characteristics, such as outcome ascertainment
(especially for diabetes), adjustment variables, and ex-
posure contrast.
As with many reviews of observational data, the risk of
publication bias cannot be completely ruled out and it
can be hypothesized that studies with significant and
positive results are more widely disseminated than those
with non-significant and/or negative results. We consid-
ered producing funnel plots to explore the presence of
publication bias across studies included in the meta-
analyses. However, as a rule of thumb, tests for funnel
plot asymmetry should not be used when there are fewer
than 10 studies in the meta-analysis because test power
is usually too low to distinguish chance from real asym-
metry [65]. We restricted this review to studies pub-
lished in English, due to the generalization of the
English language in scientific publications. To ascertain
if we may have omitted studies not published in English,
we ran the same search in PubMed, but limiting the re-
sults to non-English languages. We found 12 new arti-
cles (5 in Chinese, 3 in Japanese, 2 in Italian, 1 in
Spanish, and 1 in Czech), but based on abstract, none of
them met the eligibility criteria other than language.
Strengths and limitations of studies included in the
review
Most studies were not designed with environmental ex-
posures in mind. Even though there is evidence for a
cross-sectional relation between uBPA and cardiometa-
bolic disorders, results were different across studies,
even in different cycles from the same study (NHANES).
Rancière et al. Environmental Health  (2015) 14:46 Page 20 of 23Depending on the studies, possible explanations could be
incomplete adjustment for confounders, measurement
error, or differences in study design.
When studying the relation between BPA exposure
and cardiometabolic disorders, the statistical models
should be properly adjusted for confounding variables.
Dietary intake, especially high levels of processed food,
has to be considered as a major potential confounding
factor for the relationship between uBPA and metabolic
disease. It has been suggested that people with diabetes
or obesity may consume more food, either in absolute
volume or from BPA-containing packaging (plastic con-
tainers, polycarbonate drink bottles, tin cans coated with
epoxy resin, etc.), which may result in higher uBPA con-
centrations than non-diabetic or healthy weight individ-
uals. Therefore we can suggest that positive findings
observed in cross-sectional studies may be due to dietary
sources of BPA exposure that are also important predic-
tors of adiposity. Less than one-third of studies included
in this review controlled for diet, mostly via total daily
energy intake, and only 1 for possible dietary sources of
BPA exposure (canned tuna fish and bottled water con-
sumption). Thus, there is a strong need for observational
studies controlling for dietary characteristics including
potential sources of BPA exposure. Moreover, food and
drink in BPA-containing packaging are not necessarily
similar in terms of nutritional value (e.g., canned vegeta-
bles compared to processed meat, or bottled water com-
pared to sugar-sweetened beverages). Consequently,
there is a requirement for data on both dietary patterns
(e.g., overall energy intake) along with sources of dietary
exposure to BPA, as this helps disentangle real associa-
tions from confounding.
Additionally, given the potential correlation of envir-
onmental toxicants with each other, exposure to other
EDCs may be another confounding factor. Two studies
controlled for exposure to other environmental phenols
[47] or to phthalates [37]. In both studies, when added
to final multivariable models, the authors reported that
the other contaminants did not substantially change the
associations of uBPA concentrations with the studied
outcomes.
Other methodological limitations of studies relate to
BPA exposure assessment. BPA concentrations have
been mostly determined in a single urine measurement.
There is accumulating evidence that a single measure-
ment may not reflect chronic exposure to BPA: regard-
less of the timing of urine sampling (spot, first morning
void, 24 h collection), BPA concentrations were shown,
in individual adults, to considerably vary throughout the
day and the week [66]. Thus, using only a single uBPA
measurement may lead to non-differential exposure mis-
classification of the participants and bias the estimates.
The study by Snijder et al., in pregnant women, showedthat using only one uBPA measurement resulted in
underestimation of the association between maternal
uBPA and fetal growth, which was stronger and signifi-
cant when several measurements were taken into ac-
count [67]. Consequently, it would be better to increase
the number of measurements per participant. However,
in the context of large-scale epidemiological studies, the
substantial cost of the BPA assay is clearly a limitation.
Interestingly, most studies report only a single urinary
measurement yet the majority show positive associations
between uBPA levels and the outcomes of interest.
Another controversy that exists in the BPA literature
relates to the lack of knowledge on ‘deep’ compartments,
which may serve as potential sources of BPA exposure.
Before being metabolized by the liver, BPA is a lipophilic
compound. Although it was thought to be rapidly me-
tabolized and excreted, recent data showed a half-life
longer than expected, suggesting a potential accumula-
tion in body tissues such as adipose tissue [68]. In agree-
ment with this hypothesis, Fernandez et al. showed,
among 20 Spanish women, that unconjugated BPA was
detected in adipose tissue in 55 % of the samples [69].
The other key issue in the human data is the lack of
prospective data, reflecting the inherent difficulties in
performing longitudinal studies, which are costly and
time-consuming. Five studies used a prospective design
and the main outcomes differ. Although literature in this
area is rapidly increasing, the majority of studies pub-
lished have, and continue to be, of a cross-sectional na-
ture. Indeed, among the 11 studies published between 1
June 2013 and 1 August 2014, only 3 have a prospective
design. Nearly half of the publications included in this
review relied on NHANES cross-sectional data, includ-
ing a substantial number of publications using the same
study population. Consequently, it is imperative that
more prospective epidemiological data is presented, es-
pecially with outcomes related to glucose tolerance and
anthropometry, which appear to show the most consist-
ent associations. Certainly, given chronic diseases such
as diabetes develop over a timespan of many years, tim-
ing of BPA measurement would need to occur within an
etiologically relevant window before diagnosis of the
disease.
Differences in analyses and results contribute to confu-
sion about the association between BPA exposure and car-
diometabolic disorders. As Casey & Neidell highlighted,
using continuous uBPA, continuous log-transformed uBPA
or uBPA in quartiles as exposure variable can lead to lack
of consistency in results in a same data set [37]. It therefore
seems difficult to draw definitive conclusions from the
available data, and publications may be vulnerable to biases
given that the same data set can produce significant or
non-significant associations according to the different stat-
istical models utilized.
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BPA is solid-phase extraction coupled with HPLC-MS/
MS with peak focusing [13]. Overall, chromatography-
based methods are expensive and, thus, not particularly
suitable for the large numbers of samples which are re-
quired to ensure that analyses are adequately powered to
detect any association. Less expensive methods have
been proposed, focusing on BPA metabolites (e.g., BPA-
glucuronide) [70, 71]. It has been suggested that part of
the BPA measured in human samples can be due to con-
tamination during sample collection or laboratory mea-
surements [72, 73], and one of the great advantages of
studying BPA metabolites is to avoid these contamin-
ation issues. The lower cost of these methods would also
allow measuring BPA in larger populations. However, at
present, the use of urinary levels of BPA metabolites as
surrogates for BPA exposure remains to be validated.
Future research and implications
Experimental studies have suggested that BPA exposure
is associated with abnormal glucose metabolism and in-
sulin resistance. However, data from observational stud-
ies of humans supporting an association between BPA
and obesity, diabetes and CVD are still too limited in
cross-sectional studies to make definitive statements of
harm. It is imperative that more prospective studies,
with careful measurements of dietary intake, socioeco-
nomic status and urine dilution, are conducted to under-
stand the potential impact BPA exposure in humans will
have on the development of chronic disease. Concerning
the health outcomes of interest, if associations with
overweight/obesity defined according to BMI have been
much studied, there are a limited number of studies
using more accurate measures of adiposity (such as percent
body fat or fat mass). In some studies, analyses were strati-
fied by gender, age, BMI or pre-existing disease. Future
studies should continue to explore the existence of popula-
tions potentially at greatest risk for BPA-related health ef-
fects, in order to confirm or refute these first results.
Irrespective of outcome, if confirmed, reasons for differ-
ences in these associations will need further exploration.
Certainly, no epidemiological study has aimed to identify
critical windows of exposure and the risk of incident car-
diometabolic disorders. For chronic diseases which have a
long latent period, different lag times should be tested. This
should feature in future longitudinal studies, especially in
paediatric cohorts.
Even in the absence of certainty, there are growing
community concerns about the possible deleterious im-
pact of BPA on human health. In agreement with the
precautionary principle, regulations have been adopted
by a number of countries, prohibiting BPA in baby feed-
ing bottles, in food containers for young children, or in
all food and drink packaging, with the aim of reducinghuman exposure to BPA [74]. If the hypothesised associ-
ations are confirmed, this will not only provide evidence
to further limit or ban the use of BPA in the food indus-
try, but also advance the impetus to research other
health outcomes, and to further explore the impact of a
broad range of potential environmental toxins on
chronic disease. Lastly, given the recent efforts to reduce
BPA exposure, finding safe alternatives to BPA is a very
important issue. While BPA can be replaced by structurally
similar molecules, such as other bisphenols (e.g., bisphenol
S, bisphenol F), initial studies suggest similar endocrine dis-
rupting effects [75], and epidemiological studies should
now also consider exposure to BPA-replacement chemicals.Conclusion
In summary, we have shown that uBPA at levels found in
the general population is associated with increased preva-
lence of diabetes, general and abdominal obesity, and
hypertension. Additional prospective data are needed to as-
certain the nature of the relationship between BPA expos-
ure and cardiometabolic disorders. Prospective cohort
studies, with carefully collected data on dietary sources of
BPA exposure and other potential confounders, as well as
repeated uBPA measurements, are indicated and will likely
prove useful in filling this gap in the literature and clarify-
ing/explicating these complex relationships.Additional file
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